Compare Charles Schwab Corporation Common Stock (SCHW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Sanofi SA — how do they compare? Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.81B), while Sanofi SA trades at $42.71 (market cap $104.06B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SCHW | SNY | |
|---|---|---|
Market Cap | $184.81B | $104.06B |
Sector | Financials | Health |
52-Week High | $113.65 | $52.34 |
52-Week Low | $85.35 | $41.33 |
Dividend Yield | 1.2% | 5.61% |
Enterprise Value | — | $124.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $106.87, down 2.21% today, as technical indicators signal bearish momentum with price near key support at $106. Fundamentally, the company shows strength with Q2 2026 EPS beating estimates at $1.62 versus $1.56 expected, and revenue growth accelerating to $23.92B in 2025. Analyst sentiment remains positive with 57% buy ratings and a $122.14 consensus target, representing 14% upside potential from current levels.
The outlook remains favorable given strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures from Vanguard's Altruist acquisition present risks. With robust cash flow generation and improving debt metrics, SCHW offers value for long-term investors despite current bearish technical signals.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
